&NA;Lefradafiban (BIBU 104, BIBU 104XX) is an oral prodrug of fradafiban, the active glycoprotein IIb/IIIa receptor antagonist. It is currently undergoing phase II clinical development with Boehringer Ingelheim Pharma KG in Germany for use as an oral antithrombotic agent. Results from a dose-finding study were presented at the European Society of Cardiology meeting in Stockholm August 1997, and further studies using the lower doses are planned.